AC Immune Moves Closer to Clinical Studies of Anti-TDP-43 Antibody

AC Immune Moves Closer to Clinical Studies of Anti-TDP-43 Antibody
AC Immune is planning to advance its investigational anti-TDP-43 antibody into clinical testing for neurodegenerative diseases in which TPD-43 protein aggregates play a major role in brain damage, including diseases such as Alzheimer's, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration with TDP-43 pathology. The company began preclinical studies that, if successful, would pave the way for an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking permission to begin the first in-human studies.

“This milestone reinforces AC Immune’s position as a leader in developing novel therapies against neurodegenerative diseases, with our anti-TDP-43 antibody on track to become the first in the world to reach clinical development," said Andrea Pfeifer, PhD, CEO of AC Immune, in a press release.

TDP-43 has emerged as a potential therapeutic target for certain neurodegenerative diseases. This protein is normally found within the cell nucleus where it stabilizes RNA — DNA ‘blueprints’ that serve as intermediarie

Subscribe or to access all post and page content.